Winning RFID Achieves Record Revenue and Profits in Q2, H1 EPS Reaches NT$3.62

Winning RFID (6417-TW), a supplier of RFID solutions, is fully realizing the synergistic benefits of its relocation to a new facility, supported by a rebound in medical application demand. The company has achieved consecutive quarterly revenue records in Q4 2025 and Q1 2026. In Q2 2026, revenue reached a new high of NT$506 million, while post-tax net profit also set a record at NT$82.04 million, with earnings per share (EPS) of NT$1.94, exceeding expectations. The first-half EPS reached NT$3.62.

Today, Winning RFID released its latest financial report. For Q2 2026, revenue was NT$506 million, a record high. Gross margin stood at 34.71%, up 0.14 percentage points quarter-on-quarter and 3.43 percentage points year-on-year. Post-tax net profit for the quarter reached a record NT$82.04 million, increasing 15.89% sequentially and 2.01 times year-on-year. EPS was NT$1.94, surpassing market expectations.

For the first half of 2026, total revenue was NT$934 million, with a gross margin of 34.65%, up 2.85 percentage points year-on-year. Post-tax net profit was NT$153 million, up 89.13% year-on-year, and EPS was NT$3.62.

Winning RFID achieved a new performance milestone in Q2 2026, marking three consecutive quarters of record-breaking results. With the launch of its new BLE TAG product for Ambient IoT, shipments are expected to grow exponentially in the second half. Monthly revenue is projected to exceed NT$170 million going forward. Based on current order volumes and shipment pace, Q2 2026 is likely to see another record high. Full-year revenue is expected to surpass the previous record of NT$1.607 billion set in 2025.

As Winning RFID actively expands overseas, institutional investors estimate full-year 2026 EPS could reach NT$7–7.5. The company aims to earn back one full share capital by 2027.

Demand for Winning RFID’s wireless RF solutions in the medical sector is clearly rebounding. With full support from major shareholder希華 (2484-TW), the company plans to aggressively enter the Japanese market by establishing a local production line as a domestic legal entity to capture demand from Japan’s pharmaceutical and medical sectors for RFID solutions. Mass production for Japan’s vast pharmaceutical RFID market is scheduled to begin in 2028.

Winning RFID’s rapid entry into Japan’s pharmaceutical market is facilitated by its major shareholder,希華 Crystal, which inherited Japan Sekiden Co., Ltd. in 2000. This existing subsidiary, located in Yonezawa, Yamagata Prefecture, enables Winning RFID to quickly establish a local entity, leveraging existing personnel and facilities for product manufacturing and certification. Frequency component manufacturer希華 is Winning RFID’s largest institutional shareholder, holding 13.63%. Mr. Tseng Ying-Tang, Chairman of希華, also serves as Chairman of Winning RFID.